Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the CSTAR Cohort XXXII
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.70283
Abstract: This study aimed to evaluate and compare the efficacy and safety of tofacitinib versus methotrexate in the management of systemic lupus erythematosus (SLE) within a real‐world cohort, with a particular focus on mucocutaneous and musculoskeletal… read more here.
Keywords: tofacitinib versus; real world; systemic lupus; mucocutaneous musculoskeletal ... See more keywords
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-222543
Abstract: Objectives To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). Methods In an open-label, randomised controlled… read more here.
Keywords: tofacitinib versus; malignancies excluding; trial; risk factors ... See more keywords
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Sign Up to like & getrecommendations! Published in 2024 at "RMD Open"
DOI: 10.1136/rmdopen-2023-003912
Abstract: Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid… read more here.
Keywords: versus tnfi; mace; tofacitinib versus; risk ... See more keywords